Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CD59 Levels in Neuromyelitis Optica and Multiple Sclerosis

Compared with noninflammatory neurological disorders

Publish date:: January 5, 2016

High cerebrospinal fluid (CSF) levels of CD59 in patients with neuromeyelitis optica (NMO) or multiple sclerosis (MS) may reflect inflammation, damage, and/or complement activation in the central nervous system. This according to analysis of CSF levels of CD59 in 30 patients with NMO, 22 patients with MS, and 24 patients with noninflammatory neurological disorders (NINDs). Researchers found:

• CSF CD59 levels in patients with NMO and MS were higher than those in patients with NINDs.

• CSF CD59 levels decreased after treatment in patients with NMO.

• No significant correlation were found between CSF CD59 levels and clinical and laboratory parameters in NMO and MS.

Citation: Uzawa A, Mori M, Uchida T, Masuda H, Ohtani R, Kuwabara S. Increased levels of CSF CD59 in neuromyelitis optica and multiple sclerosis. [Published online ahead of print December 11, 2015]. Clin Chim Acta. doi: 10.1016/j.cca.2015.12.013.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,